Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.83 USD
Change Today +0.08 / 0.74%
Volume 38.4K
CGIX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

cancer genetics inc (CGIX) Snapshot

Open
$10.67
Previous Close
$10.75
Day High
$10.86
Day Low
$10.64
52 Week High
06/9/14 - $12.67
52 Week Low
12/3/14 - $4.83
Market Cap
106.4M
Average Volume 10 Days
60.5K
EPS TTM
$-1.84
Shares Outstanding
9.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CANCER GENETICS INC (CGIX)

Related News

No related news articles were found.

cancer genetics inc (CGIX) Related Businessweek News

No Related Businessweek News Found

cancer genetics inc (CGIX) Details

Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China. The company offers microarray based testing, a microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer; and next generation sequencing testing, a proprietary next generation sequencing tests for the diagnosis and prognosis of genomic alterations in chronic lymphocytic leukemia, myeloma, and B-cell non-hodgkin's lymphomas. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutation analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides fluorescent in situ hybridization testing, an analysis of abnormalities at the chromosomal and gene levels; histology testing, a microscopic examination of stained tissue sections; and cytology testing, a non-gynecological fluid preparation for microscopic evaluations. Further, it offers IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. Additionally, the company provides various oncology-focused tests and laboratory services to oncologists and pathologists in hospitals, cancer centers, and physician offices, as well as to biotech and pharmaceutical companies for their clinical trials. It also provides Expand Dx program for community hospital’s oncology diagnostic process; and consulting, guidance, and preparation of samples and clinical trial design. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

139 Employees
Last Reported Date: 03/16/15
Founded in 1999

cancer genetics inc (CGIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $260.3K
Vice President of Research & Development
Total Annual Compensation: $297.9K
Compensation as of Fiscal Year 2014.

cancer genetics inc (CGIX) Key Developments

ReproCELL Selects Cancer Genetics to Power Next-Generation Sequencing Services in Multi-Year Agreement

Cancer Genetics, Inc. announced that it was selected by ReproCELL, Inc. to provide next-generation sequencing (NGS) based services and molecular information to enhance ReproCELL's translational medicine initiatives. Under the terms of the agreement, CGI will perform NGS using its recently launched Focus::Hotspot™ panel. This panel targets clinically actionable and validated mutations found in several of the most common solid tumors including breast, colorectal, and lung cancers. CGI expects to process several thousand samples over the next two years at the Company's genomic lab in Hyderabad, India to aid ReproCELL in advancing its product development portfolio.

Cancer Genetics, Inc. Appoints Mandar Kulkarni as Chief Technology Officer of Cancer Genetics, India

Cancer Genetics, Inc. (CGI) announced the appointment of Mandar Kulkarni, PhD. as Chief Technology Officer (CTO) of Cancer Genetics, India, based in Hyderabad. In his role, Kulkarni will lead efforts to expand CG India's technology programs and initiatives with a focus on accelerating development and innovation. Dr. Kulkarni will report directly to Cancer Genetics CEO, Panna Sharma. Kulkarni joins CGI with over five years of experience in both clinical and genomic development and will be focused initially on three key strategic areas.

Cancer Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cancer Genetics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's revenue was $4,370,327 against $1,430,375 a year ago. Loss from operations was $4,152,044 against $3,936,841 a year ago. Loss before income taxes was $4,278,307 against loss before income taxes of $4,299,834 a year ago. Net loss was $4,278,307 or $0.44 per diluted share against net loss of $2,485,893 or $0.27 per diluted share a year ago. Net cash used in operating activities was $3,104,631 compared to $1,936,924 a year ago. Purchase of fixed assets was $83,149 compared to $144,018 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CGIX:US $10.83 USD +0.08

CGIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CGIX.
View Industry Companies
 

Industry Analysis

CGIX

Industry Average

Valuation CGIX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CANCER GENETICS INC, please visit www.cancergenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.